Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01559259 · ClinicalTrials.gov registry record · Phase 2

Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain

A Phase 2 study, sponsored by Pfizer.

Completed
Registry status
Phase 2
Development phase
394
Enrollment target

NCT01559259 is a Phase 2 study that has completed, run by Pfizer. The registered enrollment target is 394 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01559259, a Phase 2 study, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 2
Development phase
394 participants
Enrollment target

Study Summary

This study will determine the overall analgesic efficacy of three different fixed dose ibuprofen plus acetaminophen formulations compared to ibuprofen alone and to placebo.

Interventions

  • DRUG Placebo
  • DRUG Ibuprofen
  • DRUG Ibuprofen/acetaminophen

Trial Details

FieldValue
Enrollment Target 394 participants
Start Date 2012-04-10
Est. Completion 2012-09-13
Phase Phase 2

Sponsor

Pfizer

1,845 total trials

What the Registry Record Tells You About NCT01559259

The ClinicalTrials.gov registry entry for NCT01559259 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 394 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.

NCT01559259 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01559259 about?

NCT01559259 is a clinical study titled "Evaluation of the Efficacy of Novel Ibuprofen Acetaminophen Combination Formulations in the Treatment of Post-surgical Dental Pain". This study will determine the overall analgesic efficacy of three different fixed dose ibuprofen plus acetaminophen formulations compared to ibuprofen alone and to placebo.

What is the current status of trial NCT01559259?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 394 participants. The study started on 2012-04-10. Estimated completion is 2012-09-13.

What interventions are being tested in trial NCT01559259?

The interventions under investigation include: Placebo (DRUG), Ibuprofen (DRUG), Ibuprofen/acetaminophen (DRUG).

Who is sponsoring clinical trial NCT01559259?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.